Headline News

 

Bayer to acquire Perfuse Therapeutics in bid to lead ophthalmology pipeline

Posted on May 11, 2026

Madrigal bolsters MASH pipeline with Arrowhead’s PNPLA3-targeting siRNA

Posted on May 11, 2026

Johnson & Johnson’s Tremfya becomes first IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn’s disease

Posted on May 05, 2026

Johnson & Johnson’s JNJ-4804 shows promising Phase 2b results in refractory inflammatory bowel disease

Posted on May 05, 2026

Bristol Myers Squibb launches “Won’t Lose” campaign ahead of FIFA World Cup 2026

Posted on May 05, 2026

GSK’s bepirovirsen granted priority review and breakthrough therapy designation by FDA for chronic hepatitis B

Posted on May 05, 2026

AstraZeneca’s Breztri approved in the US for asthma, becoming the first and only single-inhaler triple therapy for patients aged 12 and older

Posted on May 05, 2026

FDA advisory committee votes against camizestrant combination for ESR1-mutant advanced breast cancer in a setback for AstraZeneca

Posted on May 05, 2026

FDA advisory committee backs AstraZeneca’s Truqap combination for PTEN-deficient metastatic hormone-sensitive prostate cancer

Posted on May 05, 2026

Pfizer secures three patent settlements for Vyndamax, extending exclusivity to mid-2031

Posted on May 05, 2026

Pfizer’s Elrexfio significantly improves progression-free survival in relapsed or refractory multiple myeloma

Posted on May 05, 2026

Lilly’s Omvoh delivers first ever four-year disease clearance data for an IL-23p19 therapy in ulcerative colitis

Posted on May 05, 2026

AstraZeneca’s Breztri approved in the US for asthma, becoming the first and only single-inhaler triple therapy for patients aged 12 and older

Posted on April 28, 2026

Sanofi’s Tzield approved in the US to delay onset of stage 3 type 1 diabetes in young children

Posted on April 28, 2026

Sanofi’s Cenrifki recommended for EU approval to treat non-relapsing secondary progressive multiple sclerosis

Posted on April 28, 2026